Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
By Oy, B. W., Eck, Ack, S. H., Imon, Arol, B. M, Rownscheidle, Homas and 11 more. New England Journal of Medicine, 2000
1,530 citations recorded by the source corpus.
Subfields: Pollution
View Paper: https://www.semanticscholar.org/paper/e1441ad0be2c7f574446616d9b52c57fb2ad5926
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- T. Kuhlmann
- Gueanelle Lingfeld
- Wolfgang Brück
- A. Bitsch
- J. Schuchardt
- Bernhard Hemmer
- Richard Frank
- Christian Gaser
Citations in the corpus
- An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis (2012, background): “Accordingly, T2-hyperintense lesion volume has been of interest in basic research and has been determined in most pivotal trials on disease-modifying drugs since the late nineties (Ebers, 1998; Jacobs et al., 2000; Kappos, 1998).”
- Depression in multiple sclerosis: a review (2005, background): “79 Notwithstanding that finding most recent studies have found little in the way of firm evidence that interferon treatment is likely to result in depression among people with MS. 80–82 For example, the Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis…”
- Diagnostic criteria for multiple sclerosis. (2001, background): “The matter of the clinically isolated syndromes of MS (CIS), optic neuritis, transverse myelitis or ‘a cerebellar’ syndrome, presumed indicators of a subsequently developing MS, has received a great deal of attention recently especially regarding long-term prophylactic treatment [15,16].”
- Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. (2002, result): “This is in agreement with clinical studies that showed a bene®t of immunomodulatory treatment with b-interferon starting early after disease onset (Jacobs et al., 2000; Comi et al., 2001).”
- Clinical biomarkers in drug discovery and development (2003, methodology): “Indeed, MRI studies have been used to support the registration and labelling of interferon-1-β and have shown the benefits of early interventio”